← Back

Rani Therapeutics Holdings Inc

Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on enabling oral administration of biologics and drugs as an alternative to injections. It develops the RaniPill capsule, a drug-agnostic oral delivery platform for oligonucleotides, peptides, proteins, and antibodies. Its pipeline includes RT-105 for rheumatoid arthritis, RT-116 for obesity, RT-117 for rare diseases, and RT-111, an ustekinumab biosimilar for inflammatory conditions. The company has collaborations with ProGen, Chugai Pharmaceutical, and PegBio. Founded in 2012, it is headquartered in San Jose, California.

Country
Price · split & dividend adjusted
News & notes moving RANI
RANI▲

Rani Therapeutics Appoints Michelle Gilson to Board of Directors

Rani Therapeutics has appointed Michelle Gilson, former Chief Financial Officer of Arcellx, to its Board of Directors, where she will serve as Chair of the Audit Committee. Gilson brings deep capital markets and biotech financial leadership experience, having played a central role in Arcellx’s financial strategy and its acquisition by Gilead in 2026. Her background also includes biotechnology equity research analyst roles at Canaccord Genuity, Jefferies, Nomura, Oppenheimer & Co., and Goldman Sachs. Rani Therapeutics is a clinical-stage biotherapeutics company focused on oral delivery of biologics using its RaniPill capsule technology.
RANI ▲
GlobeNewswire·45dRead more →
RANI

Rani Therapeutics grants 2 million share option to new CFO as inducement award

Rani Therapeutics Holdings granted an equity award in the form of a stock option to purchase 2,000,000 shares of its Class A common stock to Nicholas Maestas, its new Chief Financial Officer, as an inducement material to his acceptance of employment. The option, granted on July 17, 2026, has an exercise price of $0.6973 per share, equal to the closing price on the grant date, a ten-year term, and vests over four years with 25% of the shares vesting on the one-year anniversary of his employment start and the remaining shares vesting over the following 36 months in equal installments of whole shares, subject to continued service. The grant was approved by the Compensation Committee of Rani’s Board of Directors under Nasdaq Listing Rule 5635(c)(4) and is subject to the company’s 2026 Equity Inducement Plan.
RANI
GlobeNewswire·60dRead more →
Biotech & Genomic Medicine▲

Rani Therapeutics and PegBio Ink R&D Deal for Obesity and Metabolic Disease Candidates

Rani Therapeutics and PegBio have entered a research and development collaboration to evaluate multiple candidates from PegBio's obesity and metabolic disease pipeline using Rani's proprietary RaniPill platform. The companies will work together on pre-clinical development of RaniPill formulations for selected molecules, with plans to advance suitable candidates into clinical development. RaniPill is a swallowable robotic capsule designed to deliver biologics orally with injectable-like bioavailability. The agreement is expected to expand Rani's obesity portfolio beyond its existing programs, potentially adding multiple candidates with differentiated mechanisms of action.
2565.HK ▲RANI ▲
Biotech & Genomic Medicine
RTTNews·71dRead more →
RANI2

Rani Therapeutics Appoints Nicholas Maestas as CFO

Rani Therapeutics has appointed Nicholas Maestas as its new Chief Financial Officer, effective immediately. He succeeds Svai Sanford, who announced his departure in May 2026 to pursue other professional opportunities. Maestas brings more than 10 years of experience across several clinical-stage biotechnology companies, most recently serving as CFO and head of corporate strategy at Tempest Therapeutics. Prior to that, he led financial analysis and strategic planning at Alector, overseeing a collaboration with GSK. Rani Therapeutics shares closed Monday at $0.76, up 3.91%, and were trading down 0.61% in after-hours trading.
RANI
RTTNews·81dRead more →
© 2026 MarketDXAsset